Abstract:Objective In the tumour microenvironment, critical drivers of immune escape include the oncogenic activity of the tumour cell-intrinsic osteopontin (OPN), the expression of programmed death ligand 1 (PD-L1) and the expansion of tumour-associated macrophages (TA Ms). We investigated the feasibility of targeting these pathways as a therapeutic option in hepatocellular carcinoma (HCC) mouse models. Design We analysed the number of tumour-infiltrating immune cells and the inflammatory immune profiles in chemically induced liver tumour isolated from wild-type and OPNknockout (KO) mice. In vitro cell cocultures were further conducted to investigate the crosstalk between TA Ms and HCC cells mediated by OPN, colony stimulating factor-1 (CSF1) and CSF1 receptor (CSF1R). The in vivo efficacy of anti-PD-L1 and CSF1/CSF1R inhibition was evaluated in OPN overexpressing subcutaneous or orthotopic mouse model of HCC. Results The numbers of TA Ms, as well as the expression levels of M2 macrophage markers and PD-L1 were significantly decreased, but the levels of cytokines produced by T-helper 1 (Th1) cells were upregulated in tumour tissues from OPN KO mice compared with that from the controls. In addition, we observed a positive association between the OPN and PD-L1 expression, and OPN expression and TA M infiltration in tumour tissues from patients with HCC. We further demonstrated that OPN facilitates chemotactic migration, and alternative activation of macrophages, and promotes the PD-L1 expression in HCC via activation of the CSF1-CSF1R pathway in macrophages. Combining anti-PD-L1 and CSF1R inhibition elicited potent antitumour activity and prolonged survival of OPNhigh tumour-bearing mice. Histological, flow cytometric and ELISA revealed increased CD8(+) T cell infiltration, reduced TA Ms and enhanced Th1/Th2 cytokine balance in multiple mouse models of HCC. Conclusions OPN/CSF1/CSF1R axis plays a critical role in the immunosuppressive nature of the HCC microenvironment. Blocking CSF1/CSF1R prevents TA M trafficking and thereby enhances the efficacy of immune checkpoint inhibitors for the treatment of HCC.

Repression of Osteopontin by IRF8 Regulates a Novel Immunosuppressive Checkpoint

Circulating osteopontin per tumor volume as a prognostic biomarker for resectable intrahepatic cholangiocarcinoma

Osteopontin Regulates Development And Function Of Invariant Natural Killer T Cells

Osteopontin Regulates Treg Cell Stability and Function with Implications for Anti-Tumor Immunity and Autoimmunity

Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation

Osteopontin expression is essential for interferon-α production by plasmacytoid dendritic cells

Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells.

Osteopontin Small Interfering RNA Protects Mice from Fulminant Hepatitis.

Tumor Immune Checkpoints and Their Associated Inhibitors

Osteopontin Affects the Persistence of Beta-Glucan-induced Hepatic Granuloma Formation and Tissue Injury Through Two Distinct Mechanisms.

Osteopontin: Participation in Inflammation or Mucosal Protection in Inflammatory Bowel Diseases?

Human Hair Studies: III. Refractive Index of Crown Hair

Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade

Osteopontin Enhanced Hepatic Metastasis of Colorectal Cancer Cells

Loss of Optineurin Drives Cancer Immune Evasion via Palmitoylation-Dependent IFNGR1 Lysosomal Sorting and Degradation

IRF8: Mechanism of Action and Health Implications

Disruption of Tumour-Associated Macrophage Trafficking by the Osteopontin-Induced Colony-Stimulating Factor-1 Signalling Sensitises Hepatocellular Carcinoma to Anti-Pd-l1 Blockade

Expression of Osteopontin in Colonic Tissue of Patients with Inflammatory Bowel Disease

Osteopontin binds ICOSL promoting tumor metastasis

IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy

Tricyclic antidepressant plasma levels and adverse effects after overdose